Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Ribosomopathy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RPL5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RPL5 Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View RPL5 Products |
| Gene Delivery | RPL5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View RPL5 Products |
| Benchmark Ab | Anti-RPL5 Recombinant Antibody Recombinant positive control for assay validation. |
View RPL5 Products |
| Validator | RPL5 siRNA Set For knockdown verification and specificity controls. |
View RPL5 Products |
| Related Target A | MDM2 Direct binding partner of RPL5 in the nucleolar stress response pathway. |
View MDM2 Products |
| Related Target B | TP53 Downstream effector stabilized by the RPL5-MDM2 interaction. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting RPL5-MDM2 interaction in vitro | High-purity, sequence-verified RPL5 and MDM2 proteins available for robust binding assays. |
| Targeting intracellular ribosomal machinery | Premade lentiviral particles for stable cell line construction to monitor nucleolar stress. |
| Lack of Controls | Clinical-grade benchmark antibodies and recombinant positive controls included |
| False Positives | Sequence-specific validated siRNA included for target knockdown and specificity checks |
Live RPL5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the RPL5 pathway is gaining significant momentum in oncology and rare disease research. RPL5 (Ribosomal Protein L5) acts as a critical tumor suppressor by forming the 5S ribonucleoprotein (RNP) complex with RPL11 and 5S rRNA to inhibit MDM2, thereby stabilizing p53 under ribosomal stress. In cancer therapy, the focus has shifted from broad cytotoxic translation inhibitors to targeted small molecules and peptides that modulate the RPL5-MDM2-p53 axis. Additionally, because RPL5 heterozygous mutations cause Diamond-Blackfan Anemia (DBA), gene therapy and mRNA-based rescue strategies represent highly active areas of clinical investigation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | PMV Pharmaceuticals, Roche | p53-Wildtype Solid Tumors | Protein-protein interaction assays (Requires high-purity RPL5 and MDM2 recombinant proteins) |
| Gene Therapy / mRNA | Academic Medical Centers, Vertex | Diamond-Blackfan Anemia (DBA) | Functional rescue assays (Requires sequence-verified RPL5 Lentivirus) |
| Synthetic Lethality Screen | AstraZeneca, GSK | RPL5-Deficient Cancers | Knockdown verification (Requires validated RPL5 siRNA sets) |